These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 9605422)

  • 1. Mechanisms of inhibition of the thioredoxin growth factor system by antitumor 2-imidazolyl disulfides.
    Kirkpatrick DL; Kuperus M; Dowdeswell M; Potier N; Donald LJ; Kunkel M; Berggren M; Angulo M; Powis G
    Biochem Pharmacol; 1998 Apr; 55(7):987-94. PubMed ID: 9605422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reversible inhibition of human thioredoxin reductase activity by cytotoxic alkyl 2-imidazolyl disulfide analogues.
    Oblong JE; Chantler EL; Gallegos A; Kirkpatrick DL; Chen T; Marshall N; Powis G
    Cancer Chemother Pharmacol; 1994; 34(5):434-8. PubMed ID: 8070012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Parallel syntheses of disulfide inhibitors of the thioredoxin redox system as potential antitumor agents.
    Kirkpatrick DL; Watson S; Kunkel M; Fletcher S; Ulhaq S; Powis G
    Anticancer Drug Des; 1999 Oct; 14(5):421-32. PubMed ID: 10766297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Redox active disulfides: the thioredoxin system as a drug target.
    Kirkpatrick DL; Ehrmantraut G; Stettner S; Kunkel M; Powis G
    Oncol Res; 1997; 9(6-7):351-6. PubMed ID: 9406241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A stable mixed disulfide between thioredoxin reductase and its substrate, thioredoxin: preparation and characterization.
    Wang PF; Veine DM; Ahn SH; Williams CH
    Biochemistry; 1996 Apr; 35(15):4812-9. PubMed ID: 8664271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutagenesis of structural half-cystine residues in human thioredoxin and effects on the regulation of activity by selenodiglutathione.
    Ren X; Björnstedt M; Shen B; Ericson ML; Holmgren A
    Biochemistry; 1993 Sep; 32(37):9701-8. PubMed ID: 8373774
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thioredoxin reductase as a potential molecular target for anticancer agents that induce oxidative stress.
    Smart DK; Ortiz KL; Mattson D; Bradbury CM; Bisht KS; Sieck LK; Brechbiel MW; Gius D
    Cancer Res; 2004 Sep; 64(18):6716-24. PubMed ID: 15374989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of the thioredoxin system by PX-12 (1-methylpropyl 2-imidazolyl disulfide) impedes HIV-1 infection in TZM-bl cells.
    Lundberg M; Mattsson Å; Reiser K; Holmgren A; Curbo S
    Sci Rep; 2019 Apr; 9(1):5656. PubMed ID: 30948772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thioredoxin redox control of cell growth and death and the effects of inhibitors.
    Powis G; Kirkpatrick DL; Angulo M; Baker A
    Chem Biol Interact; 1998 Apr; 111-112():23-34. PubMed ID: 9679540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor imidazolyl disulfide IV-2 causes irreversible G(2)/M cell cycle arrest without hyperphosphorylation of cyclin-dependent kinase Cdk1.
    Vogt A; Tamura K; Watson S; Lazo JS
    J Pharmacol Exp Ther; 2000 Sep; 294(3):1070-5. PubMed ID: 10945861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The thioredoxin/thioredoxin reductase redox system and control of cell growth.
    Powis G; Oblong JE; Gasdaska PY; Berggren M; Hill SR; Kirkpatrick DL
    Oncol Res; 1994; 6(10-11):539-44. PubMed ID: 7620223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human IgG is substrate for the thioredoxin system: differential cleavage pattern of interchain disulfide bridges in IgG subclasses.
    Magnusson CG; Björnstedt M; Holmgren A
    Mol Immunol; 1997 Jul; 34(10):709-17. PubMed ID: 9430198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Crystal structures of reduced, oxidized, and mutated human thioredoxins: evidence for a regulatory homodimer.
    Weichsel A; Gasdaska JR; Powis G; Montfort WR
    Structure; 1996 Jun; 4(6):735-51. PubMed ID: 8805557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic interaction between thioredoxin inhibitor 1-methylpropyl 2-imidazolyl disulfide and sorafenib in liver cancer cells.
    Cao LP; Zhang C; Weng XY; Xie HY; Wu J; Zheng SS
    Hepatobiliary Pancreat Dis Int; 2020 Jun; 19(3):295-298. PubMed ID: 32247719
    [No Abstract]   [Full Text] [Related]  

  • 15. General acid/base catalysis in the active site of Escherichia coli thioredoxin.
    Chivers PT; Raines RT
    Biochemistry; 1997 Dec; 36(50):15810-6. PubMed ID: 9398311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diaryl chalcogenides as selective inhibitors of thioredoxin reductase and potential antitumor agents.
    Engman L; Cotgreave I; Angulo M; Taylor CW; Paine-Murrieta GD; Powis G
    Anticancer Res; 1997; 17(6D):4599-605. PubMed ID: 9494575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of thioredoxin reductase (E.C. 1.6.4.5.) by antitumor quinones.
    Mau BL; Powis G
    Free Radic Res Commun; 1990; 8(4-6):365-72. PubMed ID: 2162313
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The antitumor thioredoxin-1 inhibitor PX-12 (1-methylpropyl 2-imidazolyl disulfide) decreases thioredoxin-1 and VEGF levels in cancer patient plasma.
    Baker AF; Dragovich T; Tate WR; Ramanathan RK; Roe D; Hsu CH; Kirkpatrick DL; Powis G
    J Lab Clin Med; 2006 Feb; 147(2):83-90. PubMed ID: 16459166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cell line-directed screening assay for inhibitors of thioredoxin reductase signaling as potential anti-cancer drugs.
    Kunkel MW; Kirkpatrick DL; Johnson JI; Powis G
    Anticancer Drug Des; 1997 Dec; 12(8):659-70. PubMed ID: 9448705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glutathione- and thioredoxin-related enzymes are modulated by sulfur-containing chemopreventive agents.
    Hu Y; Urig S; Koncarevic S; Wu X; Fischer M; Rahlfs S; Mersch-Sundermann V; Becker K
    Biol Chem; 2007 Oct; 388(10):1069-81. PubMed ID: 17937621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.